Safety and efficacy of B cell maturation antigen ‐directed CAR T ‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14293 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Utkarsh Goel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis, B-Cell Maturation Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Clinical trials evaluating chimeric antigen receptor (CAR) T‐cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the safety and efficacy of CAR T‐cell therapy in this patient population. We retrospectively reviewed eight consecutive patients with RRMM and AL amyloidosis who were treated with standard of care CAR T‐cell therapy. Cytokine release syndrome was seen in 75% of patients (grade ≥3: 0%) and immune effector cell‐associated neurotoxicity syndrome (grade 1) in only one patient. Low‐grade cytopenias were common (any grade/grade ≥3: neutropenia 62.5%/37.5%, anemia 37.5%/0%, thrombocytopenia 25%/0%). CAR T‐cell therapy led to rapid and deep responses with a median time to best response of 43 days and a hematologic very good partial response or better rate of 62.5%. Overall, we found that commercial CAR T‐cell therapy was feasible, and effective in patients with RRMM and concurrent AL amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
- Cleveland Clinic Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
- United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA.
- Department of Hematology/Medical Oncology, The Medical University of South Carolina, Charleston, South Carolina, USA.
- Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA.
- University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.
ORCID-Profile: Utkarsh Goel, Hamza Hashmi, Faiz Anwer
Zitieren
APA
Goel, U., Dima, D., Davis, J., Ahmed, N., Shaikh, H., Lochner, J., Abdallah, A. O., Khouri, J., Hashmi, H., & Anwer, F. (2024). Safety and efficacy of B cell maturation antigen ‐directed CAR T ‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis. European Journal of Haematology. https://doi.org/10.1111/ejh.14293
Vancouver
Goel U, Dima D, Davis J, Ahmed N, Shaikh H, Lochner J, et al. Safety and efficacy of B cell maturation antigen ‐directed CAR T ‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis. European Journal of Haematology. 2024. doi:10.1111/ejh.14293
BibTeX
@article{Goel2024,
author = {Goel, Utkarsh and Dima, Danai and Davis, James and Ahmed, Nausheen and Shaikh, Hira and Lochner, Jonathan and Abdallah, Al-Ola and Khouri, Jack and Hashmi, Hamza and Anwer, Faiz},
title = {Safety and efficacy of B cell maturation antigen ‐directed CAR T ‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14293}
}
EUVIMED